Abstract 130P
Background
Neoadjuvant treatment of immune checkpoint inhibitors have shown a high pathologic complete response (pCR) rate in patients with dMMR/MSI-H, locally advanced colorectal cancer (LACRC). Cadonilimab (AK104), a novel bispecific antibody simultaneously targeting PD-1 and CTLA-4, was designed to boost anti-tumor activity with a favorable safety profile. Here, we primary reported the efficacy and safety of AK104 in the neoadjuvant treatment of dMMR/MSI-H LACRC, while concurrently exploring the potential for surgery avoidance.
Methods
The study was a multi-cohort, phase 2 trial, consisted of Cohort A (locally advanced colon cancer) and B (Locally Advanced Rectal Cancer). Patients (pts) with dMMR/MSI-H, LACRC were enrolled to receive AK104 (10mg/kg, iv, d1, q3w) for up to 8 cycles. The primary endpoint is the complete response rate (CR, pCR plus cCR). Secondary endpoints include MPR rate, R0 resection rate, DFS, OS, and safety.
Results
From April 2023 to August 2024, 34 pts were enrolled (26 in Cohort A and 8 in Cohort B). Baseline characteristics of pts are listed in the table. 34 pts had at least 2 cycles of treatment. In Cohort B, 4 pts completed the entire neoadjuvant treatment, and all reached the cCR. Currently, 13 pts (12 in Cohort A and 1 in Cohort B) received surgical resection, and the R0 resection rate was 100%. The pCR rate was 84.6% (11/13) and the MPR rate was 100 % (13/13). The median DFS was not reached. Treatment-related adverse events (TRAEs) occurred in 18/34(53%) pts. 5 /34 (14.7%) pts experienced grade 3-4 treatment-related adverse events (TRAEs), which included adrenocortical hypofunction (1 pt), myocarditis (1 pt), myositis (2 pts), and thrombocytopenia (1pt). No grade 5 AEs were observed. Table: 130P
Characteristics | Cohort A, N=26 | Cohort B, N=8 |
Age (years, median range) | 52 (18, 73) | 55 (48,68) |
Gender | ||
Female | 11 (42) | 1 (13) |
Male | 15 (58) | 7 (87) |
ECOG PS | ||
0 | 18 (69) | 6 (75) |
1 | 8 (31) | 2 (25) |
Clinical T category | ||
cT3 | 6 (23) | 5 (62) |
cT4a | 20 (77) | 3 (38) |
Clinical N category | ||
N+ | 26 (100) | 7 (88) |
N0 | 0 (0) | 1 (12) |
Conclusions
Cadonilimab showed promising efficacy with an outstanding pCR rate and manageable safety profile in locally advanced dMMR/MSI-H colorectal cancer patients. This trial is still ongoing and needs long-term follow-up.
Clinical trial identification
NCT05815290.
Legal entity responsible for the study
The authors.
Funding
Akeso Biopharma.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
146P - Neoadjuvant adebrelimab combined with chemotherapy for adenocarcinoma of esophagogastric junction: A single-arm, single-center, phase II clinical trial
Presenter: Jinqiang Liu
Session: Poster Display session
Resources:
Abstract
147P - Serplulimab combined with chemotherapy in the neoadjuvant treatment of resectable oesophageal squamous cell carcinoma: A single-arm phase II trial
Presenter: Zixiang Wu
Session: Poster Display session
Resources:
Abstract
148P - Neoadjuvant camrelizumab plus metronomic chemotherapy in patients with advanced esophageal squamous cell carcinomas: A randomized phase II trial
Presenter: JIE LIU
Session: Poster Display session
Resources:
Abstract
149P - Toripalimab and chemotherapy as first line combination in advanced thymic carcinoma: A prospective, single-arm, phase II trial
Presenter: Kai Zhu
Session: Poster Display session
Resources:
Abstract
150P - Interim results of the multicenter phase II study on induction pembrolizumab plus chemotherapy followed by radiotherapy in locally advanced head and neck cancer
Presenter: Tatiana Antonova
Session: Poster Display session
Resources:
Abstract
151P - Anti-tumor T cell response and immunoselection under combined GARP:TGF-?1/PD-1 blockade
Presenter: Grégoire de Streel
Session: Poster Display session
Resources:
Abstract
152P - TACTI-003 Cohort B: Eftilagimod alpha (Soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head & neck squamous cell carcinoma with PD-L1 negative
Presenter: Martin Forster
Session: Poster Display session
Resources:
Abstract
153P - Combination of Tim-3 blockade TQB2618 with PD-1 blockade for patients with immunotherapy-resistant recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): Preliminary results from a phase II study
Presenter: Cheng Xu
Session: Poster Display session
Resources:
Abstract
154P - Casdozokitug (casdozo, CHS-388), a first-in-class IL-27 antagonistic antibody, as monotherapy in treatment-refractory non-small cell lung cancer (NSCLC)
Presenter: Aung Naing
Session: Poster Display session
Resources:
Abstract
155P - Tarlatamab for patients with small cell lung cancer: 6-8 hour outpatient vs 48 hour inpatient monitoring in cycle 1
Presenter: Anne Chiang
Session: Poster Display session
Resources:
Abstract